[go: up one dir, main page]

AR079526A1 - Vacuna multivalente contra los teschovirus porcinos y otros organismos que provocan enfermedades en los cerdos - Google Patents

Vacuna multivalente contra los teschovirus porcinos y otros organismos que provocan enfermedades en los cerdos

Info

Publication number
AR079526A1
AR079526A1 ARP100104743A ARP100104743A AR079526A1 AR 079526 A1 AR079526 A1 AR 079526A1 AR P100104743 A ARP100104743 A AR P100104743A AR P100104743 A ARP100104743 A AR P100104743A AR 079526 A1 AR079526 A1 AR 079526A1
Authority
AR
Argentina
Prior art keywords
prrsv
antigen
vaccine
pigs
immunogenic
Prior art date
Application number
ARP100104743A
Other languages
English (en)
Inventor
Diana M Jordan
Axel Neubauer
Abby Rae Patterson
Michael B Roof
Eric M Vaughn
Joseph G Victoria
Elida Bautista
Original Assignee
Boehringer Ingelheim Vetmed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed
Publication of AR079526A1 publication Critical patent/AR079526A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Una composicion inmunogena o vacuna, y un método de tratamiento y un kit. La composicion inmunogena es util para tratar, prevenir y aminorar la gravedad de síntomas clínicos asociados con organismos causantes de enfermedades en cerdos, utilizando uno o más antígenos de Teschovirus Porcino junto con un antígeno del otro organismo causante de enfermedades en cerdos y un vehículo farmacéuticamente aceptable. Reivindicacion 6: La composicion segun una cualquiera de las reivindicaciones 1 a 5, caracterizada porque dicho al menos un componente inmunogeno comprende un antígeno de PCV2, PRRSV o una de sus combinaciones. Reivindicacion 8: La composicion segun la reivindicacion 6 o 7, caracterizada porque dicho antígeno de PRRV se selecciona del grupo que consiste en PRRSV atenuado, PRRSV inactivado, una subunidad inmunogena de PRRSV, un plásmido que contiene secuencias de ADN de PRRSV en el mismo, y sus combinaciones. Reivindicacion 9: La composicion segun una cualquiera de las reivindicaciones 6 a 8, caracterizada porque dicho antígeno de PCV2 es la proteína ORF2 o uno de sus fragmentos inmunogenos. Reivindicacion 10: La composicion segun una cualquiera de las reivindicaciones 6 a 9, caracterizada porque dicho antígeno de PRRSV se selecciona del grupo que consiste en un antígeno de la vacuna PRRS mLV de Ingelvac, vacuna PRRS ATP de ingelvac, PRRS KV de Ingelvac, y sus combinaciones.
ARP100104743A 2009-12-18 2010-12-17 Vacuna multivalente contra los teschovirus porcinos y otros organismos que provocan enfermedades en los cerdos AR079526A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28814509P 2009-12-18 2009-12-18

Publications (1)

Publication Number Publication Date
AR079526A1 true AR079526A1 (es) 2012-02-01

Family

ID=43533126

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100104743A AR079526A1 (es) 2009-12-18 2010-12-17 Vacuna multivalente contra los teschovirus porcinos y otros organismos que provocan enfermedades en los cerdos

Country Status (4)

Country Link
US (1) US20110150770A1 (es)
AR (1) AR079526A1 (es)
TW (1) TW201141517A (es)
WO (1) WO2011075379A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
PL1968630T3 (pl) 2005-12-29 2018-08-31 Boehringer Ingelheim Vetmedica, Inc. Multiwalentne immunogenne kompozycje PCV2
PT3127551T (pt) 2005-12-29 2020-10-09 Boehringer Ingelheim Animal Health Usa Inc Composição imunogénica de pcv2 para atenuar os sintomas clínicos em porcos
EP2859900A1 (en) 2006-12-11 2015-04-15 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
PH12013502436A1 (en) * 2011-05-27 2014-01-20 Sinovet Jiangsu Biopharm Co Ltd Combined vaccines for prevention of porcine virus infections
CN105327344B (zh) * 2011-08-01 2019-03-05 普莱柯生物工程股份有限公司 含有猪圆环病毒2型抗原与副猪嗜血杆菌抗原的疫苗组合物及其制备方法与应用
US8906385B2 (en) 2011-12-01 2014-12-09 University Of Maryland, College Park Interferon-inducing porcine reproductive and respiratory syndrome virus isolate
US10279028B2 (en) 2012-04-24 2019-05-07 Ohio State Innovation Foundation Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome
CN104797269A (zh) * 2012-04-24 2015-07-22 俄亥俄州国家创新基金会 用于治疗和预防猪繁殖与呼吸综合征的组合物和方法
CN103784951B (zh) * 2012-11-01 2017-06-30 普莱柯生物工程股份有限公司 预防和治疗猪的继发感染的呼吸系统疾病的抗原组合物及其制备方法和应用
SG11201505089YA (en) 2012-12-28 2015-07-30 Boehringer Ingelheim Vetmed Method of making a mycoplasma vaccine
CN110227151B (zh) 2012-12-28 2024-06-14 勃林格殷格翰动物保健有限公司 包含支原体抗原的免疫原性组合物
WO2014187822A1 (en) * 2013-05-22 2014-11-27 Boehringer Ingelheim Espana, S.A. Method for the reduction of pcv-2 in a herd of swine
US9993544B2 (en) * 2014-05-23 2018-06-12 Boehringer Ingelheim Vetmedica Gmbh Recombinant classical swine fever virus (CSFV) comprising substitution in the TAV epitope of the E2 protein
WO2017162720A1 (en) * 2016-03-23 2017-09-28 Intervet International B.V. A vaccine for intradermal application against pcv2 and prrs virus infection
US10279031B2 (en) * 2016-05-11 2019-05-07 Phibro Animal Health Corporation Composition comprising antigens and a mucosal adjuvant and a method for using
ES2942749T3 (es) * 2016-11-03 2023-06-06 Boehringer Ingelheim Vetmedica Gmbh Vacuna contra el parvovirus porcino y el virus del síndrome reproductivo y respiratorio porcino, y métodos de producción de la misma
CN109806389B (zh) * 2019-02-22 2022-03-22 河南省农业科学院畜牧兽医研究所 一种副猪嗜血杆菌三价灭活疫苗及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
JPS60500673A (ja) 1983-03-08 1985-05-09 コモンウエルス　セラム　ラボラトリ−ズ　コミツシヨン 抗原活性を有するアミノ酸配列
EP1792996A1 (en) * 2005-12-01 2007-06-06 Consejo Superior de Investigaciones Cientificas Nucleic acid sequences encoding vaccines against Porcine reproductive and respiratory syndrome virus (PRRSV)

Also Published As

Publication number Publication date
US20110150770A1 (en) 2011-06-23
TW201141517A (en) 2011-12-01
WO2011075379A1 (en) 2011-06-23

Similar Documents

Publication Publication Date Title
AR079526A1 (es) Vacuna multivalente contra los teschovirus porcinos y otros organismos que provocan enfermedades en los cerdos
CO6290791A2 (es) Vacunas y composiciones inmunogénicas que contienen nuevas cepas del circo virus porcino tipo 2b para inmunizar cerdos contra pmws
CL2022003085A1 (es) Anticuerpos contra sars-cov-2
MX2009008577A (es) Prevencion y tratamiento contra la enfermedad asociada a arcovirus porcion sub-clinica.
CL2021002582A1 (es) Vacunas contra el circovirus porcino tipo 3 (pcv3), su producción y usos
MX356667B (es) Uso de una composicion inmunogenica de pcv2 para reducir los sintomas clinicos en cerdos.
PE20030285A1 (es) Vacunacion en dosis unica con mycoplasma hyopneumoniae
AR053711A1 (es) Combinacion de vacunas para circovirus porcina y helicobacter y metodos de utilizacion
PE20130324A1 (es) Proteinas de fusion que comprenden un antigeno prame (dage)
AR068363A1 (es) Reduccion de infecciones concomitantes en cerdos mediante el uso de antigeno pcv2
AR058870A1 (es) Composiciones inmunogenicas de pcv2 multivalentes y metodos de producir composiciones de este tipo
CO6511229A2 (es) Metodos para reducir la actividad viricida en composiciones pcv-2 y composiciones pcv-2 con una inmunogeicidad mejorada
PE20121544A1 (es) Vacuna de pcsk9
CO5700788A2 (es) Composiciones y metodos para inmunoterapia especifica de wt1
AR085272A1 (es) Cepa del prrsv (virus del sindrome reproductor y respiratorio porcino) europea
BRPI1013780B8 (pt) Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica
CL2012002431A1 (es) Composición inmunogénica que comprende al menos 0,2 µg de proteína recombinante orf2 del circovirus porcino de tipo 2 (pcv2) por dosis y un adyuvante seleccionado de ácido acrílico, ácido metacrílico y cualquier polímero de los mismos, la cual es efectiva para disminuir los síntomas clínicos asociados con una infección pcv2.
EA201170813A1 (ru) Способы и композиции на основе pcv2 для лечения свиней
PE20090478A1 (es) Compuestos de indol macrociclicos como inhibidores de la proteasa del virus de la hepatitis c
MX2021012695A (es) Vacuna de subunidad del virus de la fiebre porcina clasica (csfv).
AR080313A1 (es) Composiciones de virus de moquillo canino (cdv) recombinante y sus usos
CU23632A1 (es) Métodos para la identificación de candidatos terapéuticos contra enfermedades causadas por flavivirus y moléculas antivirales.
CL2009000287A1 (es) Composicion que comprende un alfavirus salmonideo (sav) inactivado y al menos un componente seleccionado de una bacteria muerta/inactivada, otro virus inactivado, un hongo, un parasito y un material antigenico derivado de la bacteria, virus, hongo o parasito anterior; metodo para elaborar la composicion y uso del sav.
MX2022012618A (es) Aptameros para uso en el tratamiento de infecciones por coronavirus.
BR112012027643A2 (pt) métodos para a inativação de um orthomixovírus, para a preparação de uma vacina, e , composição imunogênica

Legal Events

Date Code Title Description
FB Suspension of granting procedure